Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Moderna Inc Stock Research

MRNA

103.53USD-3.21(-3.01%)Market Closed
Watchlist

Market Summary

USD103.53-3.21
Market Closed
-3.01%

MRNA Alerts

MRNA Stock Price

MRNA RSI Chart

MRNA Valuation

Market Cap

39.4B

Price/Earnings (Trailing)

32.68

Price/Sales (Trailing)

3.7

EV/EBITDA

30.6

Price/Free Cashflow

-52.31

MRNA Price/Sales (Trailing)

MRNA Profitability

EBT Margin

33.48%

Return on Equity

25.36%

Return on Assets

19.83%

Free Cashflow Yield

-1.91%

MRNA Fundamentals

MRNA Revenue

Revenue (TTM)

10.7B

Revenue Y/Y

-92.76%

Revenue Q/Q

-81.53%

MRNA Earnings

Earnings (TTM)

1.2B

Earnings Y/Y

-162.81%

Earnings Q/Q

-1.8K%

Price Action

52 Week Range

95.02217.25
(Low)(High)

Last 7 days

-4.7%

Last 30 days

-6.8%

Last 90 days

-14.1%

Trailing 12 Months

-20.2%

MRNA Financial Health

Current Ratio

3.46

MRNA Investor Care

Buy Backs (1Y)

3.79%

Diluted EPS (TTM)

2.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for MRNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
Hoge Stephen
sold
-1,694,850
112
-15,000
president
2023-09-15
Bancel Stephane
acquired
-
-
17,893
chief executive officer
2023-09-13
AFEYAN NOUBAR
sold
-1,645,520
109
-15,000
-
2023-09-08
Klinger Shannon Thyme
sold
-59,722
107
-557
chief legal officer
2023-09-07
Klinger Shannon Thyme
acquired
-
-
1,138
chief legal officer
2023-09-06
Garay Arpa
sold
-62,219
108
-574
chief commercial officer
2023-09-06
AFEYAN NOUBAR
sold
-1,614,090
107
-15,000
-
2023-09-05
Klinger Shannon Thyme
sold
-12,815
111
-115
chief legal officer
2023-09-05
Hoge Stephen
sold
-35,659
111
-320
president
2023-09-05
Garay Arpa
acquired
-
-
1,140
chief commercial officer

1–10 of 50

Which funds bought or sold MRNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-14
IMS Capital Management
sold off
-100
-1,203,150
-
-%
2023-09-12
Farther Finance Advisors, LLC
added
22.81
-498
17,010
-%
2023-09-07
Triatomic Management LP
added
19.32
-37,877
637,875
0.65%
2023-09-05
Delos Wealth Advisors, LLC
unchanged
-
-32.00
122
-%
2023-09-01
Manhattan West Asset Management, LLC
added
116
607,201
1,454,960
0.54%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-2,817,430
10,670,700
0.10%
2023-08-23
Stonebridge Capital Advisors LLC
unchanged
-
-7,859
29,768
-%
2023-08-23
WOLVERINE TRADING, LLC
added
635
2,608,890
3,120,890
-%
2023-08-22
Asset Dedication, LLC
unchanged
-
-23,000
87,000
0.01%
2023-08-22
COMERICA BANK
new
-
29,000
29,000
-%

1–10 of 41

Latest Funds Activity

Are funds buying MRNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRNA
No. of Funds

Schedule 13G FIlings of Moderna

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
7.10%
27,282,173
SC 13G/A
Feb 01, 2023
blackrock inc.
6.8%
26,115,224
SC 13G/A
Jan 19, 2023
baillie gifford & co
11.66%
44,786,746
SC 13G/A
Feb 14, 2022
bancel stephane
7.64%
31,538,184
SC 13G/A
Feb 14, 2022
flagship ventures fund iv general partner llc
2.8%
11,460,435
SC 13G/A
Feb 04, 2022
blackrock inc.
6.8%
27,661,473
SC 13G
Jan 26, 2022
baillie gifford & co
11.29%
45,772,079
SC 13G/A
Jul 12, 2021
blackrock inc.
4.8%
19,390,725
SC 13G/A
Mar 01, 2021
baillie gifford & co
11.18%
44,691,386
SC 13G/A
Feb 16, 2021
flagship ventures fund iv general partner llc
2.9%
11,460,435
SC 13G/A

Recent SEC filings of Moderna

View All Filings
Date Filed Form Type Document
Sep 20, 2023
144
Notice of Insider Sale Intent
Sep 18, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Sep 15, 2023
4
Insider Trading
Sep 15, 2023
4
Insider Trading
Sep 13, 2023
144
Notice of Insider Sale Intent
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
8-K
Current Report
Sep 08, 2023
144
Notice of Insider Sale Intent
Sep 08, 2023
4
Insider Trading

Peers (Alternatives to Moderna)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
145.2B
26.6B
4.13% 21.09%
18.2
5.46
0.75% 21.34%
94.5B
27.4B
-0.16% 19.51%
17.24
3.45
-0.48% 32.56%
39.4B
10.7B
-6.80% -20.18%
32.68
3.7
-53.67% -91.41%
37.7B
10.0B
-1.71% 27.59%
14.15
3.78
-6.23% 29.40%
MID-CAP
11.2B
1.7B
5.59% 6.81%
63.29
6.67
29.01% 1345.90%
4.5B
-
-3.04% 140.92%
-7.66
48.33
54.84% -12.96%
3.1B
-
-4.51% -22.98%
-23.78
37.44
122.90% 54.78%
2.0B
80.2M
6.46% -52.82%
-6.01
24.54
42.17% -39.82%
SMALL-CAP
1.5B
121.2M
4.38% -25.42%
-5.13
12.17
-70.36% -531.73%
980.2M
15.3M
-15.63% 3.04%
-5.4
64.02
1090.59% -36.57%
664.9M
1.6B
-12.64% -74.33%
-1.13
0.42
23.74% 60.24%
221.7M
-
-17.58% -90.72%
-1.05
1.62
116.83% 16.61%
146.7M
-
-8.84% -84.12%
-0.74
0.61
113.96% -15.19%
112.7M
2.1M
-6.14% -67.90%
-1.12
54.83
487.70% -8.66%
4.1M
-
-12.28% -96.10%
-0.05
3.21
- -129.46%

Moderna News

MarketWatch
Moderna Inc. stock underperforms Wednesday when compared to competitors.
MarketWatch,
10 hours ago
The Motley Fool
Marketscreener.com
The Wall Street Journal
The Motley Fool
The Motley Fool
The Motley Fool
Is Moderna Stock a Top Buy?.
The Motley Fool,
5 days ago
Morningstar
6 Undervalued Biotech Stocks.
Morningstar,
6 days ago
Marketscreener.com

Returns for MRNA

Cumulative Returns on MRNA

14.0%


3-Year Cumulative Returns

Risks for MRNA

What is the probability of a big loss on MRNA?

99.2%


Probability that Moderna stock will be more than 20% underwater in next one year

83.4%


Probability that Moderna stock will be more than 30% underwater in next one year.

49.4%


Probability that Moderna stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Moderna was unfortunately bought at previous high price.

Drawdowns

Financials for Moderna

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-29.3%10,654,000,00015,059,000,00019,263,000,00021,390,000,00022,995,000,00022,600,000,00018,471,000,00011,831,000,0007,019,000,0002,732,000,000803,000,000246,055,000106,101,00052,184,00060,209,00081,575,000106,286,000122,054,000135,068,000191,551,000192,266,000
Operating Expenses------------865,367,000620,150,000588,464,000606,879,000650,720,000630,485,000599,559,000548,334,000493,614,000476,382,000
  S&GA Expenses10.4%1,290,000,0001,169,000,0001,132,000,000958,000,000848,000,000758,000,000567,000,000445,000,000325,000,000241,000,000188,000,000135,087,000115,260,000106,747,000110,000,000121,936,000112,288,000105,188,00094,252,00074,972,00075,408,000
  R&D Expenses11.3%4,310,000,0003,872,000,0003,295,000,0002,732,000,0002,433,000,0002,144,000,0001,991,000,0002,102,000,0001,925,000,0001,656,000,0001,370,000,000728,645,000504,282,000480,587,000496,000,000528,784,000518,197,000494,371,000454,082,000404,870,667389,206,000
EBITDA-100.0%-5,413,000,0009,948,000,000-15,968,000,00016,564,000,00013,531,000,000--687,063,000-704,472,000-563,923,000-456,516,000-475,315,000-484,000,000-500,148,000-457,886,000-414,665,000---
EBITDA Margin-100.0%-0.360.52-0.690.730.73--0.25-0.88-2.29-4.31-9.04-8.04-6.13-4.31-3.40---
Interest Expenses---25,000,000---14,000,000---9,000,000---6,000,000---2,998,000--
Earnings Before Taxes-83.8%818,000,0005,041,000,0009,575,000,00013,330,000,00015,665,000,00016,254,000,00013,285,000,0007,604,000,0003,820,000,000640,000,000-744,000,000-596,743,000-488,136,000-506,400,000-515,000,000-532,515,000-489,453,000-444,632,000-384,408,000-324,200,000-325,638,000
EBT Margin-100.0%-0.330.500.620.680.720.720.640.540.23-0.93-2.42-4.61-9.64-8.55------
Net Income-74.8%1,207,000,0004,784,000,0008,362,000,00011,765,000,00014,055,000,00014,638,000,00012,202,000,0007,061,000,0003,495,000,000598,000,000-747,000,000-597,269,000-487,484,000-505,424,000-514,000,000-532,157,000-489,273,000-444,934,000-384,734,000-324,410,666-325,954,000
Net Income Margin-100.0%-0.320.430.550.610.650.660.600.500.22-0.93-2.42-4.61-9.62-8.54------
Free Cashflow-100.0%-612,000,0004,581,000,0006,201,000,0009,215,000,00013,031,000,00013,336,000,00011,386,436,0009,083,037,0005,007,746,0001,959,523,000613,169,000-371,194,000-451,223,000-490,522,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42017Q4
Assets-9.3%21,88424,12525,85826,05626,04327,60924,66920,92316,15312,6947,3374,6513,4862,0681,5891,5911,6851,8061,9621,084
  Current Assets-12.6%10,59912,12213,43114,29713,56316,35016,07113,42510,96911,7036,2983,5772,7971,2501,1291,0941,0971,1411,563783
    Cash Equivalents10.5%3,8013,4413,2053,0272,8735,0486,8605,5505,6035,4422,6241,5061,762392248174152503670148
  Inventory-2.3%7157329492,0771,9211,9421,44196564349447.00---------
  Net PPE----------------204209213212139
Liabilities-6.2%4,9355,2626,7358,0648,05810,53410,52410,7999,4498,8564,7761,891539427415339347360432459
  Current Liabilities-10.7%3,1233,4994,9236,8076,8129,2389,1289,9578,8408,4414,3891,474162135143148162159223191
Shareholder's Equity-10.1%16,94918,86319,12317,99217,98517,07514,14510,1246,7043,8382,5612,7602,9471,6411,1751,2481,3351,4421,530-
  Retained Earnings-7.5%17,01918,39918,32016,85515,81213,6159,9585,0901,757-1,023-2,244-1,970-1,740-1,620-1,496-1,369-1,246-1,111-982-621
  Additional Paid-In Capital-73.6%1937311,1731,4882,4133,6444,2115,0034,9314,8604,8024,7264,6763,2682,6692,6182,5822,5572,53872.00
Shares Outstanding-0.8%38138438538739640240340440240039939538135333733132932981.0064.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-122.8%-2269934,9816,6299,65313,41213,62011,5749,1915,1042,027664-336-420-459-450-424-363-330-319-319
  Share Based Compensation9.3%28125722620117115614213111310393.0087.0086.0083.0081.0092.0086.0079.0073.0055.0052.00
Cashflow From Investing409.5%3,852756-5,176-5,266-9,538-12,264-8,523-7,575-5,427-1,536-1,672-1,351-59.34-319-15.00-139-13699.00-373-505-990
Cashflow From Financing19.7%-2,689-3,348-3,448-3,883-2,844-1,541-87344.0076.001,4812,0332,0212,00763052.005965716771,2278681,321
  Buy Backs-20.7%2,5623,2323,3293,7842,7781,480857--------------

MRNA Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 344$ 4,749$ 2,206$ 10,815
Operating expenses:    
Cost of sales7311,3811,5232,398
Research and development1,1487102,2791,264
Selling, general and administrative332211637479
Total operating expenses2,2112,3024,4394,141
(Loss) income from operations(1,867)2,447(2,233)6,674
Interest income1044021355
Other income (expense), net14(13)(34)(26)
(Loss) income before income taxes(1,749)2,474(2,054)6,703
(Benefit from) provision for income taxes(369)277(753)849
Net (loss) income$ (1,380)$ 2,197$ (1,301)$ 5,854
(Loss) earnings per share:    
Basic (in usd per share)$ (3.62)$ 5.55$ (3.39)$ 14.66
Diluted (in usd per share)$ (3.62)$ 5.24$ (3.39)$ 13.85
Weighted average common shares used in calculation of (loss) earnings per share:    
Basic (in shares)381396383399
Diluted (in shares)381419383423
Product sales    
Revenue:    
Total revenue$ 293$ 4,531$ 2,121$ 10,456
Other revenue    
Revenue:    
Total revenue$ 51$ 218$ 85$ 359

MRNA Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 3,801$ 3,205
Investments4,6586,697
Accounts receivable2321,385
Inventory715949
Prepaid expenses and other current assets1,1931,195
Total current assets10,59913,431
Investments, non-current6,1058,318
Property, plant and equipment, net2,2802,018
Right-of-use assets, operating leases130121
Deferred tax assets1,480982
Other non-current assets1,290988
Total assets21,88425,858
Current liabilities:  
Accounts payable310487
Accrued liabilities1,4902,101
Deferred revenue1,0402,038
Income taxes payable4748
Other current liabilities236249
Total current liabilities3,1234,923
Deferred revenue, non-current692673
Operating lease liabilities, non-current10492
Financing lease liabilities, non-current843912
Other non-current liabilities173135
Total liabilities4,9356,735
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, par value $0.0001; 162 shares authorized as of June 30, 2023 and December 31, 2022; no shares issued or outstanding at June 30, 2023 and December 31, 202200
Common stock, par value $0.0001; 1,600 shares authorized as of June 30, 2023 and December 31, 2022; 381 and 385 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively00
Additional paid-in capital1931,173
Accumulated other comprehensive loss(263)(370)
Retained earnings17,01918,320
Total stockholders’ equity16,94919,123
Total liabilities and stockholders’ equity$ 21,884$ 25,858
Stéphane Bancel
2700
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.